Navigation Links
The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
Date:2/24/2009

trated that this compound showed an improvement in the visual appearance of scars in a comparative study versus a category leading OTC national brand name scar cream.

Dr Richard Rosenbloom MD, PhD, Exec VP, and COO of Quigley Pharma stated: "It is gratifying to see one of our patented and positively tested formulations come closer to benefiting the consumer and providing a return on our investment."

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) lozenges, clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities and Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or
'/>"/>

SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
2. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
3. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
4. CEL-SCI Corporation Releases Letter to Shareholders
5. Chemstar Corporation Offers Comprehensive Deep Cleaning Programs to Combat Salmonella, Listeria, and E. coli in Retail Supermarkets
6. Christie Cookie Recalls Certain Lots of Peanut Butter Cookie Dough Due to Expanded Recall by Peanut Corporation of America
7. AGA Medical Corporation Launches Web-Based Stroke Education and Awareness Program Featuring Professional Football Player Tedy Bruschi
8. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
9. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
10. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
11. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... On Thursday, July 10, 2014, the ... Industrial Average finished the day 0.42% lower at 16,915.07, and ... were broad based as eight out of ten sectors ended ... Index ended the day at 711.88, down 0.02%, while the ... has initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... , , , Funding and ... NEW YORK, Dec. 14 The Microbicides Development Programme announced ... conducted among almost 9,400 women in four African countries, found ... of HIV infection. , Reacting to today,s announcement, AVAC executive ...
... InterMune, Inc. (Nasdaq: ITMN ) today announced that Steve ... the 2009 DB-Biotech Boston Confab on December 15, 2009 at ... audio webcast of the presentation, investors and other interested parties ... corporate website at www.intermune.com. The company recommends logging on ...
Cached Medicine Technology:AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial 2AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial 3
(Date:7/13/2014)... is a professional supplier of funeral products. According to the ... in the global market. Recently, the company has announced its ... special offer for all the newly released items. , ... are made with superb materials. As is commonly noted, a ... to the departed saint. MillionaireCasket.com is always here to help. ...
(Date:7/13/2014)... to get the best treatment and variations in the ... survival for blood cancer patients still varies widely between ... of survival in European adults to date, published in ... is that 5-year survival for most cancers of the ... likely reflecting the approval of new targeted drugs in ...
(Date:7/13/2014)... Carolinas Healthcare System celebrated today the ... HealthCare System - Anson located in Anson County. The ... Hospital in Wadesboro. , Located on U.S. Highway 74, ... previous facility. Situated on a 10-acre site, the new ... room drop-off, helipad, healing garden, and 15 beds. With ...
(Date:7/13/2014)... identifies a novel genetic and molecular pathway in ... up potential new therapeutic strategies for an enigmatic ... a chronic inflammatory disorder of the esophagus. The ... foods and an over-accumulation in the esophagus of ... body,s immune system). EoE can cause a variety ...
(Date:7/13/2014)... 2014 Chromatography system is a ... various types of biological samples such as air ... mixture into two phase, namely mobile phase and ... run over the stationary phase, followed by the ... provide the separation of mixture. Chromatography system plays ...
Breaking Medicine News(10 mins):Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3
... fibronectin can predict whether a pregnant woman is at ... risk for pre-term births are women with previous pre-term ... suffer from diabetes and/or hypertension. The current approach for ... is the use of a clinical scoring system, ...
... technology born of genetic ,engineering, and known as naked ... such as multiple ,sclerosis and rheumatoid arthritis. , ... In multiple sclerosis (MS) and ,rheumatoid arthritis (RA), the ... myelin sheath of nerves falls ,victim, while in RA, ...
... requiring heart bypass ,speeds recovery in children undergoing ... clinical trial published in The Lancet., , ... underwent long and difficult surgeries. Following trauma or ... concentrations plummet. Many experts thought this was an ...
... derivatives from garlic may potentially play a role in ... review published in a recent issue of Nutrition in ... effect of garlic on risk factors for heart disease. ... LDL ("bad") ,cholesterol and blood pressure. It may also ...
... painkillers to ease the agony of terminally ill patients ... the practice, comparing it to euthanasia, but doctors at ... doses of drugs such as morphine live just as ... research published in The Lancet medical journal, they compared ...
... Antibiotcs seem to treat or prevent the symptoms of autism ... is affected by autism. Currently there are no treatments for ... found that a subset of patients with autism who experience ... by antibiotic vancomycin. ,Interestingly the study was done ...
Cached Medicine News:
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established.,NOTE: Use of a heavy-duty wire guide is recommended....
Medicine Products: